This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone
Journal of Cancer Research and Clinical Oncology Open Access 20 January 2017
-
Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients
Journal of Hematology & Oncology Open Access 07 March 2012
-
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
Leukemia Open Access 13 September 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Pardanani A, Lasho TL, Finke C, Mai M, McClure RF, Tefferi A . IDH1 and IDH2 mutation analysis in chronic and blast phase myeloproliferative neoplasms. Leukemia 2010, e-pub ahead of print 22 April 2010.
Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058–1066.
Patnaik MM, Lasho TL, Finke C, Gangat N, Caramazza D, Holtan SG et al. WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia 2010, e-pub ahead of print 20 May 2010.
Tefferi A, Vardiman JW . Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872–1885.
Watanabe T, Nobusawa S, Kleihues P, Ohgaki H . IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174: 1149–1153.
Nobusawa S, Watanabe T, Kleihues P, Ohgaki H . IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009; 15: 6002–6007.
Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010; 24: 105–109.
Acknowledgements
This study is supported, in part, by grants from the Myeloproliferative Disorders Foundation, Chicago, IL, USA. AP is partially supported by a grant from the Henry J Predolin Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Pardanani, A., Patnaik, M., Lasho, T. et al. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia 24, 1370–1372 (2010). https://doi.org/10.1038/leu.2010.98
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.98
This article is cited by
-
Acute myeloid leukemia with isolated del(5q) is associated with IDH1/IDH2 mutations and better prognosis when compared to acute myeloid leukemia with complex karyotype including del(5q)
Modern Pathology (2020)
-
The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
Annals of Hematology (2017)
-
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone
Journal of Cancer Research and Clinical Oncology (2017)
-
IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
Leukemia (2016)
-
Stem cell origin of myelodysplastic syndromes
Oncogene (2014)